109,972 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Acquired by Velan Capital Investment Management LP

Velan Capital Investment Management LP acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the 4th quarter, HoldingsChannel reports. The firm acquired 109,972 shares of the company’s stock, valued at approximately $817,000. Avalo Therapeutics accounts for about 0.7% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 18th largest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in shares of Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after acquiring an additional 3,754 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $145,000. Northern Trust Corp purchased a new stake in Avalo Therapeutics during the 4th quarter worth about $168,000. Finally, Bank of Montreal Can bought a new position in Avalo Therapeutics in the 4th quarter worth about $446,000. 87.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AVTX. Jefferies Financial Group began coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $23.00 price target on the stock. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Stifel Nicolaus began coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $36.00 price target for the company. Finally, HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $3.91 on Monday. The company’s fifty day moving average price is $5.78 and its 200-day moving average price is $7.76. Avalo Therapeutics, Inc. has a one year low of $3.39 and a one year high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Monday, May 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.18). Equities research analysts predict that Avalo Therapeutics, Inc. will post -19.07 EPS for the current fiscal year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.